Imugene Ltd (ASX:IMU, OTC:IUGNF) has welcomed Dr Jakob Dupont as a non-executive director, with Dr Dupont to bring his 20-plus years of experience in industry and academic drug development – specialising in oncology and other therapeutic areas – to the team.
Dr Dupont is well known for his contributions to the development and approval of 10 oncology drugs and has orchestrated successful development programs for numerous drugs.
About Dr Dupont
He is currently the global head of Research and Development at Nasdaq-listed Atara Biotherapeutics (NASDAQ:ATRA) Ltd, where he oversees all research and development including three clinical-stage programs spanning Phase 1 through to Phase 3, and numerous pre-clinical programs.
Further to this, he oversees key collaborations with academic and pharma partners, holds leadership and guidance roles for various teams within the business and acts as a spokesperson to investors and the board of directors.
Dr Dupont spent more than six years in various roles at Genentech/Hoffman-La Roche including as vice president, global head of Breast and GYN Cancer Development and a further five years at Oncomed Pharmaceuticals as senior vice president and chief medical officer.
He is also an independent director at Apexigen Ltd and a Scientific Advisory Board member at AMBRX.
His knowledge has seen him published 48 times in peer-reviewed journals and has extensive established relationships with global clinical and research oncologists, collaborative groups, industry and investors.
Imugene’s MD and CEO Leslie Chong is looking forward to drawing on Dr Dupont’s expertise, saying, “Dr Dupont is a key opinion leader across immune-oncology, cell therapy and early oncology drug development, bringing a wealth of industry, research and academic experience to enhance the strength of our already world-class board of directors.
"We look forward to what we expect will be an invaluable contribution from Dr Dupont as we continue to develop our clinical pipeline."